Comparison of Pharmaceutical Performance

Slides:



Advertisements
Similar presentations
Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Advertisements

Chapter 9: Parenteral Dosages
1 Ratios and Proportions A ratio is a comparison of like quantities. A ratio can be expressed as a fraction or in ratio notation (using a colon). One common.
Inhaler technique is it important?. Compton et al (2006) Review of evidence from 6 European countries ( Spain, Italy, France, Germany, Netherlands, UK)
Perform and therapeutic benefit of Using a Nebuliser / Inhaler correctly Devangna Bhatia.
Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
Mosby items and derived items © 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 3 Administration of Aerosolized Agents.
Therapeutic Aerosols Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
Demonstrably Difficult to Compound Drug Products Kathleen Anderson, Pharm. D. Division of Prescription Drug Compliance and Surveillance Office of Compliance.
1 Suspension 1. 2  Suspension:  Suspension: A suspension is a two-phase system consisting of a finely divided solid particles dispersed in liquid, or.
Calculating Oral Dosage
Inhalation Devices Heba Abd El-fattah Sabry Pharm D.
Padma GM Rao Associate Dean & Chairperson Pharmacy Practice, RAKCOPS RAKMHSU Pharmaceutics Dispensing & General Pharmacy-ll.
Oral Medication Labels and Dosage Calculation
Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.
Copyright © 2015 Cengage Learning® Chapter 6 Oral Medication Labels and Dosage Calculation.
Andrew R Henry. 3M Drug Delivery Systems, Morley Street, Loughborough, Leicestershire. United Kingdom. The correlation chart illustrated the effect changing.
Andy Cooper and Chris Blatchford 3M Drug Delivery Systems Ltd, Loughborough, Leicestershire, LE11 1EP Text Here – Body copy will vary in size depending.
Comparing the Surface Energetics and Mechanical Properties of two Potential Sub-micron Sugar Bulking Excipients for use in Low-dose, Suspension Formulations.
P Bainbridge and P A Jinks 3M Drug Delivery Systems Loughborough Leicestershire LE11 1EP Text Here – Body copy will vary in size depending on how much.
3M Drug Delivery Systems 3 Chris Blatchford & Gemma Nixon, 3M Drug Delivery Systems, Morley St, Loughborough, UK. Graham Hargrave, Tim Justham & Edward.
3M Drug Delivery Systems 3 Introduction The headspace of pressurized metered dose inhaler (MDI) canisters is filled by the vapor of volatile components,
3M Drug Delivery Systems 3 Introduction A combination MDI product has been developed containing two active drug substances (designated as A and B) in solution,
Taper DPI FeatureImpact Efficacy Safety Compliance Cost High Efficiency  Equivalent lung dose achieved in- vitro with approximately 50% lower delivered.
Loss of Dose Patient Simulation Dan Clarke 3M Drug Delivery Systems Loughborough Leicestershire LE11 1EP Testing was performed using two suspension formulations.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Copyright © 2015 Cengage Learning® Chapter 6 Oral Medication Labels and Dosage Calculation Cheryl Proffitt RM, MSN September 2015.
Lesley Williams, Victoria Velasco, Dan Heyworth & Lisa Bradley 3M Health Care Ltd, Up Brooks, Clitheroe, Lancashire, BB7 1NX, England 3 Drug Delivery Systems.
Thomas Bell and Andy Cooper 3M Drug Delivery Systems Ltd, Loughborough, Leicestershire, LE11 1EP 3M Drug Delivery Systems Monitoring of Droplet Size Changes.
Pharmacy Practice, Fourth Edition
Author : Development and characterization of Budesonide pressurized metered dose inhaler (pMDI) using gamma scintigraphy Sharma.
Introduction Methodology Results Conclusion Reference
Oral Medication Labels and Dosage Calculation
Prescribing, preparation and administration of the IMP including maintaining blinding V6.0 17/01/17.
Ventoline 0.4 Mg Annostus ventolin prescription prices ventolin hfa 90 mcg actuation aerosol inhaler cost of ventolin inhaler buy albuterol online order.
Comparing abuse of extended-release versus immediate-release opioid analgesics adjusted for number of prescriptions and morphine-equivalent dose Stephen.
John Haughney, David Price, Neil C. Barnes, J
Vaccine Code Set Management Services Pilot
Rahul Kumar Verma1, Hooman Yari and Lucila Garcia-Contreras1 
Group members: Firdaus | Sofia | Nurainiza | Hafizah
Medical Dosage Calculations A Dimensional Analysis Approach
Chapter 3 Administration of Aerosolized Agents
12 months before treatment 12 months after treatment
A Primer on Medication Delivery Systems in COPD Management
A Primer on Medication Delivery Systems in COPD Management
The Aerosol Drug Management Improvement Team
AEROSOL THERAPY.
Determination of the preferred tongue position for optimal inhaler use
RESULTS AND DISCUSSION
Volume 151, Issue 4, Pages (April 2017)
The Aerosol Drug Management Improvement Team
The Aerosol Drug Management Improvement Team
PHARMACEUTICAL AEROSOLs
The Aerosol Drug Management Improvement Team
The Aerosol Drug Management Improvement Team
Total drug dose by device and condition while delivering 1 mL of ribavirin (5 min for the small-particle aerosol generator [SPAG] or 2 min for the vibrating.
Particle-size analysis
Presentation transcript:

Comparison of Pharmaceutical Performance DEVELOPMENT OF CICLESONIDE 60 ACTUATION HFA pMDIs TO MATCH THE PHARMACEUTICAL PERFORMANCE OF THE 120 ACTUATION PRODUCT USING SLEEVED CAN (CAN IN CAN) TECHNOLOGY M.R. Butler 1, H. Müller 2, and A. Bell 3 1 3M Health Care Ltd., Loughborough, Leicestershire, UK, 2 ALTANA Pharma AG, Konstanz, Germany,3 sanofi-aventis, Crewe, Cheshire, UK Header Figure 2: X-ray Images of Sleeved Canister – 18pts Bold White Introduction Figure 3. Compari son of TLMD for 60 and 120 Actuation Ciclesonide inhalers Comparison of Ciclesonide 80mcg TLMD for 60 In - vitro TLMD Dose Proportionality of and 120 Actuation Inhalers Ciclesonide 60 and 120 Actuation Ciclesonide is a corticosteroid, which is converted to an active metabolite (desisobutyryl-ciclesonide) in the lungs. In clinical trials, ciclesonide solution HFA based metered dose inhalers have been shown to be effective in the treatment of persistent asthma in adults (18 years and over), with lung deposition estimated to be approximately 52%. Inhalers Image of base of can reaching the internal depth stop T L M D ( m c g / a t u i o n ) 6 A P k S z e 1 2 9 8 7 R 2 = 1 20 40 60 80 100 120 140 160 180 Product Strength (mcg/actuation) Mean TLMD (mcg/actuation) 60 Actuation 120 Actuation Error bars represent 1SD Error bars represent 1SD Background Interference fit of aluminium sleeve onto 5ml aluminium canister Ciclesonide inhalers are formulated with propellant HFA 134a and ethanol in three strengths delivering individual doses of 40, 80 and 160 mcg/actuation and are available in two pack sizes delivering a minimum of 60 and 120 actuations. The container and closure for both pack sizes are the same except for the size of the canister used. The 120-actuation product uses a 10mL aluminium canister. For the 60-actuation product, a ‘sleeved’ (can in can) canister was developed, which incorporates a 5mL canister inserted inside an aluminium sleeve (refer to Figures 1 and 2). Therefore, by maintaining the same external dimensions for both product pack sizes, it became feasible to use the same actuator, labelling and packaging, as well as the same automated product manufacturing and packaging processes [1]. Figure 4. Comparison of FPD for 60 and 120 Actuation Inhalers Comparison n of Ciclesonide 40mcg FPD for 60 and In - vitro FPD Dose Proportionality of Ciclesonide 60 and 120 120 Actuation Inhalers Actuation Inhalers The consideration of headspace is important since, if not matched, the amount of propellant in the vapour phase would be different leading to slightly differing concentrations of active drug in the formulation (possibly leading to non-comparability in the in-vitro pharmaceutical performance between product pack sizes). The use of the sleeved canister successfully enables the matching of the headspace between the two pack sizes. The output of the exercise to maintain comparable headspace is detailed in Table 1 [2]. F P D ( m c g / a t u i o n ) 6 A k S z e 1 2 3 5 R 2 = 1 = 0.9999 0.0 20.0 40.0 60.0 80.0 100.0 120.0 140.0 20 40 60 80 100 120 140 160 180 Product Strength (mcg/actuation) FPD (mcg/actuation) 120 Actuation 60 Actuation Error bars represent 1SD Conclusions Figure 1. Schematic Diagram of a 10ml Canister and a 5ml Sleeved (Can in Can) Canister The investigations have demonstrated that the in-vitro pharmaceutical performance of ciclesonide 60 and 120 actuation inhalers is comparable across the three product strengths. This comparability was obtained for the 60-actuation product by the use of the sleeved canister, which ensured that the headspace between the two canisters was equivalent. 5ml Sleeved (Can in can) canister 10ml Canister Comparison of Pharmaceutical Performance References In vitro performance for both the 60 and 120 actutation pack sizes was evaluated to confirm equivalence. Through Life Medication Delivery (TLMD) (Uniformity of Content) and particle size analysis were determined following pharmacopeial guidelines [3, 4 and 5]. Figure 3 compares the TLMD for 80 mcg Ciclesonide pMDIs for the 120 and 60 actutation packs. Figure 4 compares the Fine Particle Dose (defined as the dose < 5 μm) for 40 mcg Ciclesonide pMDIs for the 120 and 60 actutation packs. For both the TLMD and FPD, the in-vitro dose proportionality was determined to confirm that the pack sizes remained comparable across the different product strengths. [1]. J.M.Moore, L. Bradley, P.Charnock and S.Brown (2004), “Container Closure System Solutions for Delivering Low Numbers of Doses from a Pressurised Metered Dose Inhaler”, Respiratory Drug Delivery IX, 333-336 [2]. M. Butler and H. Müller (2004), “Development of Alvesco® 60 Actuation pMDIs to Match the Pharmaceutical Performance of the 120 Actuation Product Using Sleeved Can (can in can) Technology”, DDL 15 Proceedings, 61-64 [3]. ”Uniformity of Delivered Dose”, Preparations for Inhalation, General Dosage Forms, European Pharmacopoeia 4th edition, 552-556, 2002 [4]. “Preparations for Inhalation: Aerodynamic Assessment of Fine Particles”, Methods of Analysis (2.9.18), European Pharmacopoeia 4th Edition, 216-219, 2002 [5]. “Metered Dose Inhalers and Dry Powder Inhalers”, <601> Aerosols Physical Tests, USP 24, 1896-1912, 2000 Represents volume of formulation in canister at first use An in-vitro feasibility exercise was performed to demonstrate whether comparability in pharmaceutical performance between the two pack sizes could be achieved. A key consideration in this exercise was whether the headspace, defined as the percentage of the canister that does not contain formulation in the liquid phase, could be made consistent between the pack sizes. 3 Drug Delivery Systems Enabling your success